JPMorgan Ups Puma Target To $131 After Surveying 25 Oncologists
October 04, 2017 at 08:18 AM EDT
JPMorgan analyst Cory Kasimov believes shares still have upside potential as Nerlynx's sales trajectory "appears underappreciated." The analyst reiterates an Overweight rating on Puma shares.
